Message

From: CFD-SRT [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=3D7963607C714138900DD470D99B1174-CFD-SRT]
Sent: 7/29/2019 4:56:29 PM
To: Calvin Willhite [calvinwillhite@hotmail.com]
Subject: RE: TIME-SENSITIVE - IMPORTANT TSCA SACC AD HOC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

The Agency had a FACA meeting of the Chemical Safety Advisory Committee in 2016 on 1-bromopropane, but you are saying you were on a much earlier panel hosted by NTP. NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of 1-bromopropane. Reprod. Toxicol. 18(2): 157-187.

There was a letter peer review of the Agency's (OPPT) draft risk assessment for TCE (2013), but I am unclear about the public comment remark. Did you complete the letter peer review and publicly comment at a separate time?

Thanks,
Sharlene

Sharlene R. Matten, Ph.D.
Senior Biologist
Office of Science Coordination and Policy
Exposure Assessment, Coordination, and Policy Division
U.S. Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington D.C. 20460
e-mail: matten.sharlene@epa.gov
Tel: 202-564-0130

From: Calvin Willhite <calvinwillhite@hotmail.com>
Sent: Monday, July 29, 2019 11:22 AM
To: CFD-SRT <CFD-SRT@epa.gov>
Subject: Re: TIME-SENSITIVE - IMPORTANT TSCA SACC AD HOC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Sharlene,

Being here is DC I can't get you a scan of the pdf of the 2004 paper by the NTP panel (of which I was a member) and PubMed gives me only the title:

NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of 1-bromopropane. Reprod. Toxicol. 18(2): 157-187.

As I recall the panel members names are shown on page 158 of that publication.

As for the TCE work on cardiovascular malformations in rodents, it will take me a few minutes to dig that up along with a paper in Toxicology on TCE.

Calvin Willhite

From: CFD-SRT <CFD-SRT@epa.gov>
Sent: Monday, July 29, 2019 8:09 AM
To: Calvin Willhite <calvinwillhite@hotmail.com>
Subject: RE: TIME-SENSITIVE - IMPORTANT TSCA SACC AD HOC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Calvin,

Thank you for your prompt response and interest in the September and October TSCA SACC meetings.

I shall look at your responses to the four questions. I have a couple of clarifying questions.

1. 1-bromopropane. When was the NTP CERHR Panel? Please provide a reference to the risk analysis you mentioned.
2. TCE. When was the TERA analysis panel? Who requested that the TERA panel do an analysis, e.g., specific company or companies? Was this a public meeting? Do you have a copy of your public statement that you could send along?

Best regards,
Sharlene

Sharlene R. Matten, Ph.D.
Senior Biologist
Office of Science Coordination and Policy
Exposure Assessment, Coordination, and Policy Division
U.S. Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington D.C. 20460
e-mail: matten.sharlene@epa.gov
Tel: 202-564-0130

From: Calvin Willhite <calvinwillhite@hotmail.com>
Sent: Saturday, July 27, 2019 11:27 AM
To: CFD-SRT <CFD-SRT@epa.gov>
Subject: Re: TIME-SENSITIVE - IMPORTANT TSCA SACC AD HOC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Hello Sharleen,

We have not met in person, but perhaps will do so this next week at the Holiday Inn.

I am available the dates you list and can best contribute to:

1-bromopropane (where I served on the NTP CERHR Panel and published its risk analysis - this could be taken as a public statement on this material).

TCE (I served on the TERA analysis panel that considered the developmental toxicology and did make public statements on the web cast)

carbon tetrachloride (no previous panel work, but I have published 2 studies in rodents wherein CCl4 was a experimental test group)

I did manage research risk assessment contracts on PCE when I was an employee with State of California during promulgation of the MCL for drinking water.

I have no financial or other interests in these 3 substances.

Hope this helps. Being a DFO is no easy task.

Calvin Willhite

From: CFD-SRT <CFD-SRT@epa.gov>
Sent: Thursday, July 25, 2019 3:47 PM
Subject: FW: TIME-SENSITIVE - IMPORTANT TSCA SACC AD HOC Member Request for responses to 4 Questions regarding "Impartiality": 5 chemical risk evaluations that will be reviewed by the TSCA SACC

Greetings!

I've addressed this message to prospective or current TSCA SACC ad hoc members, "bcc," to avoid inadvertent replies to all.

Thank you again for your participation on the TSCA SACC.

The TSCA SACC has a very busy schedule in 2019 with meetings scheduled from June through December 2019. On December 19, 2016, EPA published a list of 10 chemical substances that are the subject of the Agency's initial chemical risk evaluations, as required by TSCA § 6(b)(2)(A). The docket numbers, problem formulations, scope documents and supplemental documents for the 10 chemical substances that EPA initiated the risk evaluation process for in December 2016 can be found here:

- Pigment Violet 29 (TSCA SACC meeting, June 2019)
- 1, 4 Dioxane (TSCA SACC meeting, July 29-Aug 2, 2019)
- Cyclic Aliphatic Bromide Cluster (HBCD) (TSCA SACC meeting, July 29-Aug 2, 2019)
- 1-Bromopropane TBD
- Methylene Chloride TBD
- N-Methylpyrrolidone TBD
- Perchloroethylene TBD
- Trichloroethylene TBD
- Carbon Tetrachloride - TBD
- Asbestos - TBD

Future meetings will focus on the Agency's draft risk evaluation for the remaining seven (7) chemicals: 1-bromopropane, methylene chloride, N-Methyl-2-pyrrolidone (NMP), perchloroethylene, trichloroethylene, carbon tetrachloride, and asbestos.

For planning purposes, please indicate your interest in participating as an ad hoc member of the TSCA SACC for review of the Agency's draft risk evaluations for 1-bromopropane, methylene chloride, N-Methyl-2-pyrrolidone (NMP), perchloroethylene, trichloroethylene, carbon tetrachloride, and asbestos.

In addition, please indicate your availability for the following dates September 9-13, 2019 and October 21-25, 2019.

If you are interested and potentially available, please respond to the four questions regarding "impartiality" with respect to 1-bromopropane, methylene chloride, N-Methyl-2-pyrrolidone (NMP), perchloroethylene, and trichloroethylene (see Table below and word file attached). A public announcement of the specific draft chemical risk evaluations for the September meeting will be published with the next 2 weeks; however, we need to make sure that there is a quorum of TSCA SACC members and adequate representation of expertise (additional ad hoc members) to address the Agency's charge before the official announcement is published. I know many of you will be traveling to the upcoming TSCA SACC meeting on 1,4-dioxane and HBCD, July 29-August 2, 2019. Time is of the essence. Please contact me if you have questions or concerns.

Thank you.

Sharlene (mobile: 240-286-4365 (Fridays); office: 202-564-0130)

Sharlene R. Matten, Ph.D.
Senior Biologist
Office of Science Coordination and Policy
Exposure Assessment, Coordination, and Policy Division
U.S. Environmental Protection Agency
1200 Pennsylvania Ave., NW
Washington D.C. 20460
e-mail: matten.sharlene@epa.gov
Tel: 202-564-0130

Questions	**1-Bromopropane**	**Methylene Chloride**	**N-Methyl-2-pyrrolidone (NMP)**	**Perchloroethylene**	**Trichloroethylene**

(1) Do you know of any reason that you might be unable to provide impartial advice on the matter to come before the panel/committee/subcommittee or any reason that your impartiality in the matter might be questioned?					
(2) Have you had any previous involvement with the review document(s) under consideration including authorship, collaboration with the authors, or previous peer review functions? If so, please identify and describe that involvement.					
(3) Have you served on previous advisory panels, committees or subcommittees that have addressed the topic under consideration? If so, please identify those activities.					

(4) Have you made any public statements (written or oral) on the issue that would indicate to an observer that you have taken a position on the issue under consideration? If so, please identify those statements.					